Lifescan Inc., a wholly owned subsidiary of Johnson & Johnson, will pay claims of as many as 200,000 diabetic class members whose lawyers say the company’s blood glucose monitoring system had two potentially life-threatening design defects.
Monday’s settlement comes on top of $60 million in civil and criminal fines leveled against the company in separate suits last December.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]